Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-09-21

FDA Approved: CITALOPRAM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for Citalopram from Hikma Pharmaceuticals USA, updating the generic product's labeling and/or manufacturing details.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Citalopram (Citalopram hydrobromide)

Snippet

SUPPL AP for CITALOPRAM (CITALOPRAM)